Abstract |
NETs are neoplasms that emerge from cells of the endocrine and nervous system, with the majority being well differentiated and slow-growing tumors. Their common feature is the expression of somatostatin receptors 1-5. The imaging approach of NETs is based on the classical anatomical techniques and the radioisotopique techniques of Nuclear Medicine that assess the existence and functionality of somatostatin receptors with the help of special radiotracers, similar to somatostatin, labeled with gamma emitting radioisotopes. In addition to classical imaging, the lesions that express somatostatin receptors are detected with SPECT / CT hybrid technique (3D images) and PET / CT molecular hybrid technique, which provide both functional and anatomical information for more accurate diagnosis and assessment of response to treatment. The purpose of this study is to evaluate the role of the new SPECT / CT hybrid technique in staging and re-staging of patients with NETs, as well as to compare it with the classical somatostatin receptor scintigraphy. The study included patients with a substantiated diagnosis, candidates for treatment with somatostatin analogues or radiolabeled peptides (staging) and patients who received treatment and need a response assessment (re-staging) to determine treatment. First part of the study was the collection of patients that underwent a standard whole-body somatostatin receptor scintigraphy and SPECT / CT imaging after administration of 111In-DTPA-octreotide or 99mTc Tektrotyde. In the second part followed the processing of the scintigraphic findings and finally the comparison of the 2 techniques.
|